TY - JOUR T1 - Epidemiological impact of the paediatric live attenuated influenza vaccine (LAIV) programme on group A <em>Streptococcus</em> (GAS) infections in England JF - medRxiv DO - 10.1101/2022.12.16.22283602 SP - 2022.12.16.22283602 AU - Mary A Sinnathamby AU - Fiona Warburton AU - Rebecca Guy AU - Nick Andrews AU - Theresa Lamagni AU - Conall Watson AU - Jamie Lopez Bernal Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/12/18/2022.12.16.22283602.abstract N2 - Influenza is known to predispose to secondary bacterial infections including group A streptococcal infection (GAS) and invasive (iGAS) disease.The universal paediatric live attenuated influenza vaccine (LAIV) programme was introduced in England during the 2013/14 influenza season to directly protect children as well as indirectly protect the wider population through reduction in transmission. Nationally, the programme was implemented incrementally introducing cohorts of children from pre-school age to school age children year on year towards 2 to 16 year old coverage. In addition, a series of discrete geographical areas (pilot areas) offered LAIV vaccination to all primary school age children, allowing for a unique assessment and comparison of infection rates between pilot and non-pilot areas during roll-out.Overall reductions in incidence rates of GAS and scarlet fever were observed within most of post-LAIV programme seasons when assessing the impact of the LAIV programme among the targeted (2 to 4 years and 5 to 10 years) and non-targeted groups using incidence rate ratios (IRRs) from Poisson regressions.We assessed the overall effect of the pilot programme between the pre-introduction (2010/11-2012/13 influenza seasons) and post-introduction (2013/14-2016/17 influenza) periods using negative binomial regression by comparing the pre-to -post programme changes in incidence between the pilot and non-pilot areas (rIRR = ratio of incidence rate ratios). This showed significant reductions among the 5 to 10 years (rIRR of 0.57 (95% CI: 0.45 to 0.71; p-value: &lt;0.001)); the 2 to 4 years (rIRR of 0.62 (95% CI:0.43 to 0.90; p-value: 0.011)) and the 11 to 16 years (rIRR of 0.63 (95% CI: 0.43 to 0.90; p-value: 0.018)) for GAS infections. A non-significant reduction was also seen for iGAS in 2-4 year olds (rIRR of 0.58 (95% CI: 0.21 to 1.65; p-value=0.31)). No difference was seen for iGAS 5 to 10 year olds, or for scarlet fever in both age groups (rIRRs (95% CI) of 1.1 (0.34-3.6), 0.96 (0.66-1.39), 1.16 (0.75-1.81) for iGAS age 5 to 10, scarlet fever age 2 to 4 and 5 to 10, respectively).Our findings are compatible with the paediatric LAIV programme reducing the incidence of GAS and iGAS infections among children and support attaining high uptake of childhood influenza vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of UK Health Security Agency (UKHSA) waived ethnical approval for this work as this study was a public health evaluation with data processed for the monitoring of the LAIV immunisation programme under Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript. Data cannot be made publicly available for ethical and legal reasons, i.e. public availability would compromise patient confidentiality as data tables list single counts of individuals rather than aggregated data. ER -